<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01161953</url>
  </required_header>
  <id_info>
    <org_study_id>670-02 PBC</org_study_id>
    <nct_id>NCT01161953</nct_id>
  </id_info>
  <brief_title>Genetic Epidemiology of Primary Biliary Cirrhosis (PBC)</brief_title>
  <official_title>Understanding the Genetic Predisposition to the Development of Primary Biliary Cirrhosis (PBC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Biliary Cirrhosis (PBC) is a progressive liver disorder of unknown cause. Current
      evidence suggests that genes, the genetic material we inherit from our parents, in
      combination with environmental factors, likely play an important role in the development of
      PBC.

      This study is being done to investigate whether genes make people more likely to develop PBC.
      Discovery of these proposed genes will help us better understand how PBC developes, and
      subsequently, to apply new approaches for its prevention, diagnosis and treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mapping of Susceptibility Genes in Adult Chronic Cholestatic Liver Diseases</measure>
    <description>Adult chronic cholestatic liver diseases, such as Primary Biliary Cirrhosis (PBC), are progressive liver disorders of unknown cause. Current evidence suggests that genes, the genetic material we inherit from our parents, in combination with environmental factors, likely play an important role in the development of PBC.
This study is being done to investigate whether genes (the inherited genetic material passed from parents to their children) make people more likely to develop PBC. Discovery of these proposed genes will help us to better understand how PBC progresses, and subsequently, to apply new approaches for its prevention, diagnosis and treatment.</description>
  </primary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Primary Biliary Cirrhosis</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genetic Analysis</intervention_name>
    <description>Perform Genome Wide Association Studies.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and stool samples are collected.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who are patients at Mayo Clinic and are seen in the department of Gastroenterology
        and Hepatology are recruited by mail and carry a diagnosis of PBC. Subjects who are not
        Mayo Clinic patients are encouraged to contact the study coordinator by phone or email to
        request enrollment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women between the ages of 18-90 who have a history of PBC.

          -  PBC patients who have undergone a liver transplant are eligible.

          -  Family members (1st degree relatives) of enrolled PBC patients are eligible.

        Exclusion Criteria:

          -  Individuals with no history of PBC or those unable to provide consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konstantinos N Lazaridis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erik M Schlicht C.C.R.P.</last_name>
    <phone>507-284-4312</phone>
    <email>schlicht.erik@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik M Schlicht, CCRP</last_name>
      <phone>507-284-4312</phone>
      <email>schlicht.erik@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Konstantinos N Lazaridis, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lazaridis KN, Juran BD, Boe GM, Slusser JP, de Andrade M, Homburger HA, Ghosh K, Dickson ER, Lindor KD, Petersen GM. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology. 2007 Sep;46(3):785-92.</citation>
    <PMID>17680647</PMID>
  </results_reference>
  <results_reference>
    <citation>Juran BD, Atkinson EJ, Larson JJ, Schlicht EM, Liu X, Heathcote EJ, Hirschfield GM, Siminovitch KA, Lazaridis KN. Carriage of a tumor necrosis factor polymorphism amplifies the cytotoxic T-lymphocyte antigen 4 attributed risk of primary biliary cirrhosis: evidence for a gene-gene interaction. Hepatology. 2010 Jul;52(1):223-9. doi: 10.1002/hep.23667.</citation>
    <PMID>20578265</PMID>
  </results_reference>
  <results_reference>
    <citation>Juran BD, Atkinson EJ, Larson JJ, Schlicht EM, Lazaridis KN. Common genetic variation and haplotypes of the anion exchanger SLC4A2 in primary biliary cirrhosis. Am J Gastroenterol. 2009 Jun;104(6):1406-11. doi: 10.1038/ajg.2009.103. Epub 2009 Apr 21.</citation>
    <PMID>19491853</PMID>
  </results_reference>
  <results_reference>
    <citation>Juran BD, Atkinson EJ, Schlicht EM, Fridley BL, Petersen GM, Lazaridis KN. Interacting alleles of the coinhibitory immunoreceptor genes cytotoxic T-lymphocyte antigen 4 and programmed cell-death 1 influence risk and features of primary biliary cirrhosis. Hepatology. 2008 Feb;47(2):563-70.</citation>
    <PMID>18041714</PMID>
  </results_reference>
  <results_reference>
    <citation>Juran BD, Atkinson EJ, Schlicht EM, Fridley BL, Lazaridis KN. Primary biliary cirrhosis is associated with a genetic variant in the 3' flanking region of the CTLA4 gene. Gastroenterology. 2008 Oct;135(4):1200-6. doi: 10.1053/j.gastro.2008.06.077. Epub 2008 Jul 1.</citation>
    <PMID>18778710</PMID>
  </results_reference>
  <results_reference>
    <citation>Lammert C, Nguyen DL, Juran BD, Schlicht E, Larson JJ, Atkinson EJ, Lazaridis KN. Questionnaire based assessment of risk factors for primary biliary cirrhosis. Dig Liver Dis. 2013 Jul;45(7):589-94. doi: 10.1016/j.dld.2013.01.028. Epub 2013 Mar 11.</citation>
    <PMID>23490343</PMID>
  </results_reference>
  <results_reference>
    <citation>Lammert C, Juran BD, Schlicht E, Chan LL, Atkinson EJ, de Andrade M, Lazaridis KN. Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients. J Gastroenterol. 2014 Oct;49(10):1414-20. doi: 10.1007/s00535-013-0903-1. Epub 2013 Dec 8.</citation>
    <PMID>24317935</PMID>
  </results_reference>
  <results_reference>
    <citation>Lammert C, Juran BD, Schlicht E, Xie X, Atkinson EJ, de Andrade M, Lazaridis KN. Reduced coffee consumption among individuals with primary sclerosing cholangitis but not primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2014 Sep;12(9):1562-8. doi: 10.1016/j.cgh.2013.12.036. Epub 2014 Jan 16.</citation>
    <PMID>24440215</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2010</study_first_submitted>
  <study_first_submitted_qc>July 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2010</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Konstantinos N. Lazaridis, M.D.</investigator_full_name>
    <investigator_title>Hepatology Consultant</investigator_title>
  </responsible_party>
  <keyword>Primary Biliary Cirrhosis</keyword>
  <keyword>PBC</keyword>
  <keyword>Cholestatic Liver Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

